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The staphylokinase (Sak) is emerging as an important thrombolytic agent for the treatment of patients 
suffering from cardiovascular disease. Hence in this study, we reported the cloning, high-level 
expression, purification and characterization of the Sak variant SakφC from Staphylococcus aureus 
QT08 in Escherichia coli Bl21. The sak gene of 489 bp encoding a protein (163 amino acids) with a 
predicted molecular mass of 18.5 kDa and pI 7.28 showed 99.8 to 99.6% identity with corresponding 
sequences from S. aureus strains deposited in GenBank (AF332619, X00127, EF122253 and M57455). 
The DNA sequence (411 bp) encoding the mature Sak (15.5 kDa) truncated 27 N-terminal amino acids 
was expressed in E. coli BL21/pESak under the control of the strong promoter tac in the presence of 
isopropyl-β-D-1-thiogalactopynoside (IPTG) as inducer. The expression level of rSak was estimated at 
about 42% of the total cellular proteins by densitometry scanning, which is the highest expression level 
of rSak expressed in any E. coli system. The recombinant staphylokinase was purified by Ni
2+
-
ProBond column to a single homogeneous 16-kDa band on sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) with a specific activity of 15175 U/mg protein, a recovery yield of 58% 
and a purification factor of 2.56. The optimal pH and temperature for the rSak activity was 9 and 37°C, 
respectively. rSak was stable over a temperature range of 25 to 50°C and at pH range of 7 to 9. Metal 





completely inhibited the enzymatic activity. 
 






The obstruction of blood supply to heart muscles by the 
presence of a pathologic clot can lead to cardiovascular 
disease, a leading cause of death in human. 
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patients with acute myocardial infarction (Hennekens et 
al., 1995; Guzman and Lincoff, 1997; Sinnaeve and Van 
de Werf, 2001). The possibility of using blood-clot 
dissolving agents to dissolve thrombi offers an attractive 
means to treat this type of disease. Blood clot-dissolving 
agents currently approved for thrombolytic therapy 
include tissue plasminogen activator, urokinase, strepto-
kinase, staphylokinase and their derivatives (Collen and 
Lijnen, 1994; Sinnaeve and Van de Werf, 2001).  
Staphylokinase (Sak), an extracellular protein produced 
by Staphylococcus aureus strains, is a promising blood- 
clot dissolving agent  (Collen  and  Lijnen,  1994).  Sak  is 




both potent and safe because it lyses clots effectively in a 
fibrin-specific manner without causing any significant 
depletion of plasma proteins, and can also lyse platelet-
rich clots in animal model systems (Collen et al., 1993). 
Sak is a profibrinolytic agent that forms a 1:1 stoichio-
metric complex with plasminogen that, after conversion to 
plasmin, activates other plasminogen molecules to 
plasmin (Lijnen et al., 1991). The plasmin*Sak complex, 
unlike the plasmin*streptokinase complex, is rapidly 
inhibited by α2-antiplasmin. In a plasma milieu, Sak is 
able to dissolve fibrin clots without associated fibrinogen 
degradation (Schlott et al., 1994a). In experimental 
animal models, Sak appears to be equipotent to 
streptokinase for the dissolution of whole blood or plasma 
clots, but significantly more potent for the dissolution of 
platelet-rich or retracted thrombi (Schlott et al., 1994a).  
In addition, Sak specifically induces fibrinolysis without 
fibrinogen depletion and has higher fibrinolytic activity 
compared with other plasminogen activators like strepto-
kinase, urokinase and tissue plasminogen activator 
(Vanderschueren et al., 1995). Sak is at least as potent 
as tissue plasminogen activator (tPA) in the treatment of 
coronary artery recanalization (Armstrong et al., 2003; 
Moreadith and Collen, 2003). Furthermore, Sak has been 
shown to be more efficient than streptokinase for the 
dissolution of platelet-enriched and retracted blood clots 
(Lijnen et al., 1995; Abdelouahed et al., 1997). Hence, 
Sak has become a promising drug and stimulated much 
structural and protein engineering research. To date, sak 
gene has been cloned and expressed in different 
expression systems including Escherichia coli (Ren et al., 
2008; Mandi et al., 2009), Bacillus subtilis (Ye et al., 
1999), Streptomyces lividans (Cheng et al., 1998) and 
Pichia pastoris (Miele et al., 1999; Apte-Deshpnade et al., 
2009), and under various E. coli promoters viz., T7, 
lambda PR, tac and ptac (Lee et al., 1998), B. subtilis 
promoters of P43, Pamy and PsacB, and P. pastoris 
AOX1 promoter. 
This study aimed at cloning, high-level expression and 
characterization of a staphylokinase from S. aureus strain 
QT08 isolated from a Vietnamese patient, using pET21a+ 




MATERIALS AND METHODS 
 
Bacterial strains and vectors 
 
The bacterial strain, S. aureus QT08 (GQ247719), isolated from a 
patient at the Army Hospital No. 103 (Hanoi, Vietnam) was used as 
the source of Sak gene. E. coli DH5α (F
–
, ø80dlacZ∆M15, 







, thi-1, gyrA96, relA1) and pJET1.2/blunt vector 
(Fermentas, Thermo Fisher Scientific Inc., Waltham, USA) were 
used for DNA manipulations and amplification. E. coli BL21 (DE3) 
cells (F
–




) λ(DE3 [lacI lacUV5-T7 
gene 1 ind1 sam7 nin5]) (Fermentas, Thermo Fisher Scientific Inc., 





Darmstadt, Germany) were used for the expression of Sak. Luria-
Bertani (LB) medium containing 1% (w/v) bacto tryptone; 0.5% (w/v) 
yeast extract; 1% (w/v) NaCl; pH 7 to 7.5 was used for cultivation of 
E. coli and S. aureus QT08. The LB agar used contained an 
additional 2% (w/v) agar and 100 µg ampicillin/ml. 
 
 
Chemicals and reagents 
 
The polymerase chain reaction (PCR) reagents, restriction 
endonucleases, T4 DNA ligase and Taq polymerase, and PCR 
primers were purchased from Fermentas (Thermo Fisher Scientific 




resin was from Invitrogen 
Corp. (Carlsbad, USA), while 4-chloro-1-naphthol (horseradish 
peroxidase color development reagent) from Bio-Rad Laboratories, 
Inc. (Berkeley, USA). Human plasminogen was from MP 
Biomedicals (Santa Ana, USA), N-(p-tosyl)-gly-pro-lys 4-nitroanilide 
acetate salt (AAS) and anti-rabbit IgG (whole molecule)-peroxidase 
antibody from Sigma-Aldrich Co. (St. Louis, USA) were employed. 





Genomic and plasmid DNA isolation was carried out by methods 
previously described (Quyen et al., 2007). DNA fragments and PCR 
products were excised from a 0.8% agarose gel and purified by gel 
extraction kit (Qiagen, Venlo, The Netherlands) according to the 
manufacturer’s instruction. DNA sequencing was performed on ABI 
PRISM 3100 Avant Genetic Analyzer (Applied Biosystems Inc., 
Foster City, USA). E. coli DH5α and BL21 (DE3) cells were 
transformed using heat shock method that has been previously 
described (Quyen et al., 2007). 
 
 
DNA amplification and analysis 
 
The putative sak-coding DNA fragment was amplified from S. aureus 
QT08 genomic DNA by PCR with Taq DNA polymerase. Based on 
the DNA sequence of the sak gene from S. aureus phage 42D 
(GenBank: X06603), two oligonucleotides, SakF1 (5’-GCG AAT 
TCG CTC AAA AGA AGT TTA TTA T-3’) and SakR1 (5’-GCC TCG 
AGT TTC TTT TCT ATA ARA ACC T-3’), were designed as primers 
for introduction of the underlined EcoRI and XhoI restriction sites, 
respectively. The PCR mixture contained 2.5 µL 10X PCR buffer; 2 
µL of 2 mM dNTP; 2.5 µL of 25 mM MgCl2; 1 µL genomic DNA (50 
to 100 ng); 0.25 µL 5 U Taq polymerase and 1 µL each primer (10 
pmol), supplemented with 14.75 µL distilled water to a final volume 
of 25 µL. The thermocycler conditions were as follows: 95°C/4′; 30 
cycles of (95°C/45″, 55°C/30″, 72°C/45″); 72°C/10′. The PCR 
products amplified from the genomic DNA with both primer SakF1 
and SakR1 were inserted into the cloning vector pJET1.2/blunt, 
resulting in pJSak, and then sequenced. DNA sequencing was 
performed on ABI PRISM 3100 Avant Genetic Analyzer. Sequence 






The DNA fragment (411 bp) encoding the mature staphylokinase 
(without the signal peptide of 27 N-terminal amino acids) from S. 
aureus QT08 was amplified using pJSak as template and two 
specific primers SakF2 (5’-GCG AAT TCC ATA TGT CAA GTT CAT 





TTT TCT ATA A-3’) for introduction of the underlined NdeI and 
HindIII restriction sites, respectively. The PCR mixture contained 
2.5 µL 10X PCR buffer; 2 µL of 2 mM dNTP; 2.5 µL of 25 mM 
MgCl2; 1 µL pJSak (50 to 100 ng); 0.25 µL 5 U Taq polymerase and 
1 µL each primer (10 pmol), supplemented with 14.75 µL distilled 
water to a final volume of 25 µL. The thermocycler conditions were 
as follows: 95°C/5′; 30x (95°C/30″, 55°C/30″, 72°C/30″); 72°C/7′. 
PCR products and pET21a+ were digested with NdeI and HindIII 
and purified using gel extraction kit (Qiagen) in accordance with the 
manufacture’s instructions. It was followed by ligation of the NdeI-
HindIII digested sak products with pET21a+ linearized by the same 
enzymes, resulting in pESak under the control of the T7-promoter 
induced by IPTG (isopropyl-β-D-thiogalactopyranoside) and 
possessing the ampicillin marker. The staphylokinase Sak-his 
encoded by the plasmid pESak contains the mature staphylokinase 





The transformant E. coli BL21/pESak was cultivated in 5 ml of LB 
medium containing 5 µl of 100 mg ampicillin/ml at 37°C with 
agitation at 220 rpm. 500 µL of the overnight culture were 
transferred into 50 ml of LB medium containing 50 µL of 100 mg 
ampicillin/ml. The culture was cultivated at 37°C with agitation at 
220 rpm until an optical density (OD) at 600 nm of 0.8 was reached 
(for approximately 4 h), then 50 µL of 100 mM IPTG was added. 
The culture was continuously incubated at 28°C with agitation of 
220 rpm for 6 h of induction. Cells were harvested by centrifugation 
at 6000 rpm for 10 min at 4°C. Wet cells was used immediately for 





The fusion form rSak carrying a C-terminal 6xHis tag was 





resin (Invitrogen Corp., Carlsbad, 
USA) under hybrid conditions. To purify rSak, 350 mg wet cells from 
a 50-ml culture in LB medium were harvested by centrifugation at 
8000 rpm and 4°C for 5 min, and suspended in 10 ml of 
guanidinium lysis buffer containing 6 M guanidine hydrochloride, 20 
mM sodium phosphate, 500 mM NaCl and pH 7.8 for 1 h at 4°C. 
The cell lysate was then centrifuged at 13000 rpm and 4°C for 5 
min. A volume of 8 ml cell lysate was applied to a column 
containing 2 ml resin, which was equilibrated with denaturing 
binding buffer and incubated for 45 min at room temperature with 
gentle hand shaking for several times. The column was washed 
twice with 8 ml of denaturing wash buffer and twice with 8 ml of 
native wash buffer. The bound protein was eluted with 8 ml of 




Electrophoresis analysis and protein concentration 
 
The homogeneity and molecular mass of the rSak were determined 
by 12.5% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) (Laemmli, 1970) with Biometra equipment 
(Göttingen, Germany). Proteins were visualized by staining with 
0.1% (w/v) Coomassie Brilliant Blue R-250. Protein concentrations 
were estimated by the method of Bradford with the bovine serum 
albumin as standard (Bradford, 1976). 
 
 
Home-made production of anti-Sak serum 
 
Two New Zealand rabbits (Central Company of Veterinary Vaccine, 
Vetvaco,    Hanoi,   Vietnam)   were   used   for   anti-Sak  antibody  




production. Pre-immunized blood samples were taken from the ear 
veins of each rabbit. For the initial immunization, rabbits were 
immunized subcutaneously with purified Sak (200 µg per rabbit) 
emulsified in Freund’s complete adjuvant. Subsequent booster 
injections were given every week with 200 µg purified Sak in 
Freund’s incomplete adjuvant. Ten days after the fourth immu-
nization, the rabbits were sacrificed. The sera were collected from 
blood, portioned into Eppendorf tubes (1 ml per tube) and stored in 
deep freezer at -80°C. 
 
 
Western blot analysis 
 
Western blot analysis was carried out according to the protocol 
described in “Protein Methods” (Bollag et al., 1996). The polyvinyl 
difluoride (PVDF) membrane was embedded in the primary 
antibody (anti-Sak) serum solution diluted to 1:1000 in 1% (w/v) 
nonfat milk and incubated in the secondary anti-rabbit IgG (whole 
molecule)-peroxidase antibody solution diluted to 1:10000 in 1% 
(w/v) nonfat milk. Finally, the membrane was colored with 4-chloro-





The rSak activity was determined by using plasminogen coupled 
chromogenic substrate according to the method of Hernandez et al. 
(1990). The Sak activity was assayed by mixing 2 µL plasminogen 
(0.025 U/µL) in 10 µL of 20 mM Tris-HCl buffer pH 7.5 and 10 µL of 
appropriate dilution of rSak (0.1 µg) in 50 mM potassium phosphate 
buffer pH 7.0, and incubated at 37°C for 30 min. The 
plasminogen*Sak complexes were mixed with 40 µL of 1 mM 
chromogenic substrate AAS in 50 mM phosphate buffer, pH 7.0 and 
incubated at 37°C for 15 min. The reaction was stopped by adding 
10 µL of 0.4 M acetic acid and the absorbance was measured at 
405 nm. One unit (U) of Sak is defined as one unit of standard 
streptokinase from Sigma. One unit of standard streptokinase 
liberates a standard clot of fibrinogen, plasminogen and thrombin at 
pH 7.5 and 37°C for 10 min. The units of Sak were calculated by 
using a standard curve of pure standard streptokinase (Sigma). 
 
 
Temperature and pH optimum 
 
The pH and temperature optimum of rSak were determined by 
measuring the activity as described above using 100 mM potassium 
acetate buffer (pH 4 to 6), 100 mM potassium phosphate buffer (pH 
5.5 to 7.5) and 100 mM Tris-HCl buffer (pH 7.5 to 10) at 37°C for 30 




Temperature and pH stability 
 
For the determination of temperature and pH stability, purified rSak 
(0.1 µg for each reaction) was pre-incubated in 50 mM potassium 
phosphate buffer pH 7 at different temperatures 25 to 70°C for 0 to 
8 h, and pH range (100 mM potassium phosphate pH 6 to 7 and 
100 mM Tris-HCl pH 8 to 9) at 37°C for 0 to 8 h, respectively. The 
residual activity was then determined as above mentioned. 
 
 
Effect of metal ions and EDTA 
 
Purified rSak, 0.1 µg for each reaction, was incubated with 5 mM of 



















) and ethylenediaminetetraacetic acid (EDTA) at 37°C for 60 min, 
and in 2% (w/v) of different detergents (Tween 80, Tween  20,  SDS  




and Triton X-100) at 37°C for 30 min. The residual activity was then 
determined. All measurements were carried out in triplicate with the 
resulting values being the mean of the cumulative data obtained. 
 
 
DNA and amino acid sequence analysis 
 
Homologies of the DNA and amino acid sequences were deter-
mined with the program MegAlign DNAStar. Signal peptide was 
predicted using signal peptides prediction program SignalP 3.0 
(http://www.cbs.dtu.dk/services/SignalP/) (Nielsen et al., 1997). 
 
 
RESULTS AND DISCUSSION 
 
Gene cloning and analysis 
 
The recombinant plasmid pJSak was sequenced and the 
putative staphylokinase gene was aligned with 
sequences from GenBank using DNAStar. Nucleotide 
sequence analysis of the sak gene from S. aureus QT08 
(Figure 1A) showed a 489-bp open reading frame that 
encoded a protein of 163 amino-acid residues, with a 
predicted molecular mass of 18.5 kDa and pI 7.28 (Figure 
1A). Using the signal peptides prediction program, 
SignalP 3.0 (Nielsen et al., 1997), it was revealed that the 
most likely cleavage site between position 27 and 28 
(Figure 1A) was the predicted signal peptide site in the 
Sak sequence. The NH2-terminal amino acid sequence of 
the mature staphylokinase from S. aureus QT08 was 
identified as SSSFDKGKYKKGDDA of Sak reported 
(Schlott et al., 1994b) and Sak from S. aureus QT08 
belonged to the variant SakφC among three natural 
variants SakφC, Sak42D and SakSTAR which differ in 
only three amino acids 34, 36 and 43 in the mature 
protein: GGH, GRR, and SGH, respectively (Schlott et 
al., 1997). 
The coding sequence of sak from S. aureus QT08 
showed 99.8 to 99.6% identity with the corresponding 
sequences from S. aureus strains (AF332619, X00127, 
EF122253 and M57455), and 98.8 to 97.8% with 
sequences from S. aureus strains (U77328, EU146839 
and A17529) (Figure 1B). The deduced amino acid 
sequence of Sak had homology of 100, 99.4 to 97.8 and 
90.8% with the corresponding amino acid sequences 
from three Staphylococcus strain groups (X00127; 
AF332619, M57455, U77328, EU146839, and A17529; 
and EF122253, respectively) (Figure 1C). The nucleotide 
sequence encoding Sak from S. aureus QT08 was 




Expression and purification of rSak 
 
The DNA fragment (411 bp) encoding the mature staphy-
lokinase (rSak) truncated 27 N-terminal amino acids from 
S. aureus QT8 was inserted into pET21a+ vector at the 





plasmid pESak.  The transformant E. coli BL21/pESak 
was grown in LB medium for the rSak production. After 
IPTG induction, the cells were collected and used for 
purification and characterization. The expression level of 
rSak by E. coli BL21/pESak was determined as high as 
42% of the total proteins (Figure 2A, lanes 3 to 5) using 
Dolphin 1D software, which is the highest level of rSak 
expressed in any E. coli system till date. The expression 
level of rSak in E. coli system was previously reported to 
be 10 to 15% (Schlott et al., 1994a), 22% (Schlott et al., 
1997) and 35% (Mandi et al., 2009).  
The yield of rSak was estimated as high as 300 mg/L 
culture in this study, whereas it was reported to be 200 
mg/L fermentation broth (Schlott et al., 1994a), 70 to 500 
mg/L culture (Schlott et al., 1997), 20 mg/L (Lee et al., 
1998) and 2.8 g/L of fermentation broth (Mandi et al., 
2009), which was reported to be highest yield of rSAK 
expressed in any bacterial system till date. However, the 
yield of rSak was dependent on the cell mass productivity 
per liter fermentation broth. If any high cell-density culture 
(HCDC) technique has been developed for growing 
recombinant E. coli strain in fed-batch cultures at 
concentrations greater than 100 g (dry cell weight) per 
liter (Lee, 1996), then the yield of rSak could be 
enhanced to 3 or 4 g/L fermentation broth. The yield of 
rSak expressed in Bacillus system was also different, as 
low as 25 mg/L of culture supernatant (Behnke and 
Gerlach, 1987) and 50 mg/L (Gerlach et al., 1988), and 
as high as 337 mg/L (Ye et al., 1999) and 255 mg/L (Kim 
et al., 2001). The eukaryote system P. pastoris produced 
the prokaryote protein Sak with a lower yield of 33 to 50 
mg/L fermentation broth (Miele et al., 1999) or with a high 
yield of 1 g/L (Apte-Deshpnade et al., 2009) but with 
negligible plasminogen activation activity. In another 
study, we have expressed this rSak from S. aureus QT08 
in P. pastoris in the fully active form with a specific 
activity of 20658 U/mg and a level of 19 mg/L culture 
broth. 
rSak from S. aureus QT08 over-expressed by E. coli 
BL21/pESak cells was purified through affinity chromato-




resin to the 
homogeneity on SDS-PAGE with a molecular weight of 
approximately 15.5 kDa (Figure 2B, lanes 7 to 9). The 
purified rSak gained a specific activity of 15175 U/mg 
protein with a purification factor of 2.56 and a yield of 
58% (Table 1). Also, the Western blot analysis using 
rabbit anti-Sak antibody showed two forms of rSak, 
monomeric (~15.5 kDa) and dimeric protein (~31 kDa) 
(Figure 2C, lane 10). 
 
 
Temperature and pH optimum 
 
rSak showed an optimum temperature of 30 to 37°C and 
was active at a broad temperature range from 20 to 45°C 
with the activity of over 93% in comparison to the optimal 
activity (Figure 3A). rSak  activity  showed  the  maximum









atgctcaaaagaagtttattatttttaactgttttattgttattattctcattttcttca   60 
 M  L  K  R  S  L  L  F  L  T  V  L  L  L  L  F  S  F  S  S    20 
attactaatgaggtaagtgcatcaagttcattcgacaaaggaaaatataaaaaaggcgat  120 
 I  T  N  E  V  S  A  S  S  S  F  D  K  G  K  Y  K  K  G  D    40 
gacgcgagttattttgaaccaacaggcccgtatttgatggtaaatgtgactggagttgat  180 
 D  A  S  Y  F  E  P  T  G  P  Y  L  M  V  N  V  T  G  V  D    60 
Ggtaaaggaaatgaattgctatcccctcattatgtcgagtttcctattaaacctgggact  240 
 G  K  G  N  E  L  L  S  P  H  Y  V  E  F  P  I  K  P  G  T    80 
Acacttacaaaagaaaaaattgaatactatgtcgaatgggcattagatgcgacagcatat  300 
 T  L  T  K  E  K  I  E  Y  Y  V  E  W  A  L  D  A  T  A  Y   100 
Aaagagtttagagtagttgaattagatccaagcgcaaagatcgaagtcacttattatgat  360 
 K  E  F  R  V  V  E  L  D  P  S  A  K  I  E  V  T  Y  Y  D   120 
Aagaataagaaaaaagaagaaacgaagtctttccctataacagaaaaaggttttgttgtc  420 
 K  N  K  K  K  E  E  T  K  S  F  P  I  T  E  K  G  F  V  V   140 
Ccagatttatcagagcatattaaaaaccctggattcaacttaattacaaaggttgttata  480 
P  D  L  S  E  H  I  K  N  P  G  F  N  L  I  T  K  V  V  I    160 
gaaaagaaa                                                     489 





























Figure 1. (A) The nucleotide and deduced amino acid sequences of Sak from S. aureus QT08. The putative 
Sak signal sequence is underlined beneath the amino acid sequence. The bold amino acids are SakφC variant 
(GGH). (B) Phylogenetic analysis of the staphylokinases, based on comparison of DNA sequence and (C) 
deduced amino acid sequences of the mature proteins. The phylogenetic tree was constructed using the 
DNAStar program. The following sequences were obtained from GenBank: Sau207 (S. aureus strain QT08, 
accession no. FJ868207); Sau127 (S. aureus strain, accession no. X00127); Sau253 (S. aureus strain, 
accession no. EF122253); Sau455 (S. aureus strain, accession no. M57455); Sau619 (S. aureus strain, 
accession no. AF332619); Sau328 (S. aureus strain, accession no. U77328); Sau839 (S. aureus strain, 
accession no. EU146839); Sau529 (S. aureus strain, accession no. A17529). 




    
 
Figure 2. SDS-PAGE of the overexpressed (A) and Ni-NTA purified (B) rSak in E. coli BL21. Proteins were stained 
with Coomassie Brilliant Blue. Lane M, Molecular standards (Fermentas, Thermo Fisher Scientific Inc., Waltham, 
USA) indicated in kDa; A, E. coli pESak cell lysate before (lane 1) and after IPTG induction for 2, 4, 6 and 8 h 
(lanes 2, 3, 4 and 5, respectively); B, E. coli pESak cell lysate after IPTG induction for 6 h (lane 6) and Ni-NTA 
purified rSak (from E. coli pESak lysate) (lanes 7, 8 and 9). Western blot (C) of rSak expressed in E. coli (lane 10) 


























(100%) at pH 9 and 83 and 97% at pH 8.5 and 9, 
respectively (Figure 3B) in 100 mM Tris-HCl buffer. 
Moreover, in 100 mM phosphate buffer, rSak showed 
optimum activity at pH 7 (94%) and 83 and 64% at pH 6.5 
and 7.5, respectively. Our results are consistent with the 
report of the wild type Sak (Vesterberg and Vesterberg, 
1972); the optimal pH value for the Sak activity was 8.5 
for Tris-HCl buffer (pH 7.6 to 9.2) and 7.5 for phosphate 
buffer (pH 6.8 to 7.7).  
 
 
Temperature and pH stability 
 
rSak from S. aureus QT08 was stable at a temperature 
range from 25 to 50°C. Meanwhile, after incubation for 8 
h, the rSak activity retained above 50% in comparison to 
the original activity (Figure 4A), but less than 20% at 
temperature range of 60 to 70°C. rSak from S. aureus 
QT08 showed a similar profile in the temperature stability 
to native Sak (Fujimura et al., 1974; Schlott et al., 1994b). 
The activity of the native Sak from S. aureus after heating 
at 60°C for 2 h decreased to 11% of that of the original 
sample (Fujimura et al., 1974). Both wild type Sak42D 
and SakSAR showed a different thermal stability; Sak42D 
was inactivated more rapidly while SakSAR gradually 
inactivated for several hours at high temperature (70°C) 
(Schlott et al., 1994b). rSak from S. aureus QT08 showed 
pH stability at a pH range of 7 to 9. The residual rSak 
activity was above 40% in comparison to the original 
activity after treatment for 8 h (Figure 4B). 
 
 
Effect of metal ions 
 
In this study, the effect of various additives on the purified 




 at the 
concentration of 5 mM showed a slightly inhibitory effect 
on rSak activity, the residual activity was accounted for 
93% and 90% of the original activity, respectively (Table 
2). Moreover, the rSak activity retained over 50% by 
addition of 5 mM of Mg
2+
 and EDTA and less than 20% 














inhibited the activity of the purified rSak (Table 2). These 
similar phenomena were also observed in the catalytic 
activity of the wild type Sak treated with 20 mM of the 
metal ions (Vesterberg and Vesterberg, 1972). The 




 completely inhibited 
the Sak activity. Other metal ions showed a Sak inhibitory 















 did not show any significantly 





 showed an opposite effect on the 
rSak activity in this study and the native Sak activity 
studied by Vesterberg and Vesterberg (1972). The same 
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 affected the rate at which plasminogen was 
activated by rSak (Yarzábal et al., 1999). 
In addition, the sodium salt of EDTA at concentrations 
higher than 10 mM showed an inhibitory effect on the Sak 
activity (Vesterberg and Vesterberg, 1972), but at lower 
concentrations there was no inhibitory effect on the 
enzyme activity. In this study, at the concentration of 5 
mM, EDTA inhibited 32% enzyme activity.  
 
 
Effect of detergents on rSak activity  
 
All tested detergents inhibited enzyme activity (Table 3). 
The addition of Triton  X-100  and  Tween  20  decreased  
the rSak activity slightly by 2 to 5%, but Tween 80 by 
22%. An addition of SDS caused the most loss of 
enzyme activity; it remained only 7.3% of the original 
activity. There have been no reports so far regarding this 
issue yet. 
The study on the influence of metal ions, detergents, 
temperature and pH on the Sak activity was rather com-
plicated since, in fact, two reactions were studied in the 
assay: first, the activation of plasminogen to plasmin by 
Sak, and secondly, the digestion of substrate by plasmin. 
By adding metal salts simultaneously with the substrate, 
it was possible to observe the influence of this on the 
fibrinolytic activity, but it was not possible to isolate the 
influence of additives  on  the  activation  of  plasminogen 










Control (no additive) 100 ± 0.87 
AgNO3 8.54 ± 1.86
 
CaCl2 90.02 ± 0.12 
Co(NO3)2 20.06 ± 3.06 
CuSO4 0 
FeSO4 13.34 ± 6.67 
KCl 93.38 ± 5.57 
MgCl2 49.53 ± 3.44 
NiCl2 19.78 ± 0.39 
ZnSO4 0 
EDTA 67.63 ± 0.53 
 
a
The final concentration of additive (EDTA or inorganic salt) in 
the reaction mixture was 5 mM. 
b
Relative activity was expressed 











Control (no additive) 100
 
SDS 7.3 ± 0.18 
Tween 20 95 ± 1.45 
Tween 80 78 ± 1.67 
Triton X-100 98 ± 2.00 
 
a
The final concentration of surfactant in the reaction mixture was 
2.5%. 
b
Relative activity was expressed as a percentage of control 




to plasmin by Sak. Therefore, additives had an inhibitory 






Sak is a promising blood-clot dissolving agent for the 
treatment of patients suffering from a heart attack. It 
would be desirable to produce this protein in large 
quantities for biochemical characterization and clinical 
trials. In the present study, a sak gene from S. aureus 
QT08 was cloned and analyzed. The gene sequence 
showed only one nucleotide different from that from S. 
aureus (AF332619). The mature polypeptide chain (rSak) 
consisting of 136 amino acids was overexpressed in E. 
coli Bl21 at a high level of 42% of the total protein. The 
temperature and pH optimum for rSak were 37°C and 9, 
respectively. rSak was stable in a temperature range of 
37 to 50°C and pH 7 to 9. Additives (metal ions and 
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